Neogen Chemicals Q1 FY27: Strong start, Dahej restart and battery materials execution take centre stage

Neogen Chemicals began FY27 with a sharp improvement in profitability and a clear message that execution is now the priority. In Q1 FY27, consolidated revenue rose to INR 250.3 crore, up 34% year on year. EBITDA grew faster at INR 48.2 crore, up 53%, with margin expanding 260 basis points to 19.3%. Profit after tax increased 67% to INR 17.1 crore.

The quarter is notable because it came despite disruptions linked to the Dahej fire incident and the associated transition costs, including interim toll manufacturing and rebuild-related overheads. Management pointed to cost pass-through actions across raw materials and other inputs like freight, utilities and packaging to protect operating margins.

What drove Q1 growth: volume and mix, plus a sharper inorganic performance

Management disclosed a consolidated revenue split where organic chemicals contributed INR 194 crore and inorganic chemicals contributed INR 57 crore in Q1 FY27. Inorganic was the standout on growth, rising 158% year on year, while organic grew 18%.

The company also disclosed that exports were 30% of Q1 FY27 revenue and domestic sales were 70%, including deemed exports. It also highlighted seasonality, noting that performance tends to be stronger in the second half due to European demand ramping up in October to November and again from January, plus stronger Q4 demand for lithium-based chemicals tied to HVAC-related capex cycles.

A key emerging contributor was Neogen Ionics (the battery materials subsidiary), which recorded revenue of INR 19 crore in Q1 FY27 compared with INR 5 crore in Q1 FY26. On the call, management clarified that this revenue was largely from electrolyte salts.

Margins improved, but finance costs remain a key drag

While operating margins improved meaningfully, the financial cost line remains a pressure point. Consolidated interest cost increased 64% year on year to INR 20.8 crore in Q1 FY27. Management attributed the increase to three factors: higher debt drawdown to fund ongoing capex, higher working capital intensity due to geopolitical supply chain inflation, and delays in insurance receipts.

In this context, the board approved a fund raise of up to INR 600 crore via QIP, subject to shareholder and regulatory approvals. Management framed the QIP primarily as a deleveraging move to prepare for future opportunities in battery materials, organolithium and advanced R&D work on novel additives and electrolyte design. It also indicated that if the entire amount were used to repay debt, the potential annual interest saving could be roughly INR 40 to 50 crore, based on an 8% to 8.5% interest assumption.

Dahej restart and insurance: operational normalization expected in Q2 FY27

The Dahej fire incident continues to influence the near-term financial narrative, but the company provided quantified updates. It disclosed cumulative recoveries of INR 164 crore to date, comprising INR 155 crore in on-account insurance claims and INR 9 crore from salvage realization. It also stated that net claim receivable stood at INR 186 crore on a consolidated basis.

Operationally, reconstruction of the Dahej plant was stated to be complete, with trial runs underway. Commercial production is expected to begin in Q2 FY27. Management also described Q1 execution as resilient, stating that the temporary shutdown was managed through efficient use of toll manufacturing sites.

For investors, the Dahej restart matters for two reasons. First, it supports a return to normalized base business growth without job-work related inefficiencies. Second, it should reduce rebuild and transition costs that affected margins, even though management cautioned that some costs could persist during the ramp-up phase.

Battery materials: large capex, defined timelines, and early customer validation

Neogen Ionics is central to the company’s medium-term ambition. The presentation laid out planned capacities at Dahej SEZ and the new Pakhajan site. It stated planned total capacities of 32,000 MT for electrolyte and 5,500 MT for lithium electrolyte salts and additives across the combined footprint.

Management also disclosed a detailed capex roadmap. Total estimated project cost for Neogen Ionics’ Dahej Phase 1 and Pakhajan Phase 2 battery materials projects was stated at INR 1,795 crore. It stated INR 218 crore was incurred in Q1 FY27, taking cumulative spend to INR 1,298 crore. Dahej Phase 1 was stated at INR 428 crore with target completion by February 2027, and Pakhajan Phase 2 at INR 1,367 crore with completion expected by March 2027.

From an execution standpoint, management reiterated commissioning targets of electrolytes in H1 FY27 and electrolyte salts in H2 FY27. It said mechanical assembly for the electrolyte facility is complete and trial runs have started, with validation and approvals underway with domestic battery manufacturers.

On the electrolyte salts side, it stated provisional approvals from four major international customers and completed final site audits for US-based electrolyte manufacturers, with commercial supplies planned post final trial approvals. During the call, management linked the export opportunity to the global transition to non-FEOC supply chains, particularly in the US market, and stated that electrolyte itself is not planned for export due to shelf-life constraints, while electrolyte components such as salts and additives are exportable.

Guidance and what to track next

Management upgraded its standalone revenue guidance for FY27 to INR 950 to INR 1,050 crore, from the earlier range of INR 875 to INR 950 crore. It attributed the confidence largely to organolithium capacity hitting peak utilization in Q1 and indicated that incremental capex of around INR 10 to 15 crore may be considered after another quarter of demand visibility.

For battery chemicals, management maintained its FY27 revenue guidance of around INR 300 crore and provided a split of roughly INR 200 crore from salts and INR 100 crore from electrolytes. It also indicated that a meaningful ramp could begin from November to December 2026, ahead of January 2027 timelines associated with customer transitions.

The next few quarters will likely be judged on three measurable items. First, confirmation that Dahej commercial production ramps as guided in Q2 FY27. Second, progress in final plant trials, product approvals and the shift from trial sales to contracted supplies for electrolyte salts. Third, the balance sheet path, including the timing and quantum of QIP proceeds and insurance receipts, given elevated finance costs.

Neogen’s Q1 FY27 results show a company that is delivering growth while operating through disruption. But the more defining test is still ahead. FY27 is positioned by management as an execution year, where capex must turn into stable output and predictable offtake across both the base business and the battery materials platform.